Global Leukemia Therapeutics Market Trends 2024, Forecast To 2033
21 Feb, 2024
The leukemia therapeutics market has displayed strong growth, moving from $16.55 billion in 2023 to $17.78 billion in 2024, with a 7.4% CAGR. Historical drivers include a growing geriatric population, improved diagnostics, increasing leukemia prevalence, R&D investments, and personalized medicine expansion. Projections indicate robust growth to $23.98 billion in 2028, driven by novel immunotherapies, precision medicine focus, expanding indications for existing therapies, gene therapy adoption, and supportive care advances. Key trends include biomarker-driven approaches, combination therapies, minimal residual disease monitoring emphasis, car-T cell therapy use, and targeted therapies based on leukemia subtypes.
Global Leukemia Therapeutics Market Key Driver
The leukemia therapeutics market is witnessing growth due to the rising prevalence of leukemia. Leukemia, a type of blood cancer, has seen increased accessibility to medical treatment globally. Anticipated figures suggest around 59,610 new instances of leukemia in the United States in 2023, contributing to the growth of the leukemia therapeutics market.
Get A Free Sample Of The Global Leukemia Therapeutics Market ReportGlobal Leukemia Therapeutics Market Segments
The leukemia therapeutics market covered in this report is segmented –
1)By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2)By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3)By Molecule Type: Small Molecules, Biologics
4)By End-Users : Hospitals, Homecare, Specialty Clinics, Other End-Users
By Geography: The regions covered in the template market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the leukemia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Leukemia Therapeutics Industry Players
Novartis International AG; AbbVie Inc.; Bristol Myers Squibb Company; F. Hoffmann-La Roche AG; Sanofi S. A.; Agios Pharmaceuticals; Amgen Inc.; Argenx SE; Astellas Pharma Inc.; BioLineRx Ltd.; Celgene Corporation; Cellerant Therapeutics Inc.; Daiichi Sankyo Company Limited; Forma Therapeutics Inc.; Gilead Sciences Inc.; Incyte Corporation; Jazz Pharmaceuticals plc; Johnson & Johnson; Mirati Therapeutics Inc.; Molecular Templates Inc.; Ono Pharmaceutical Co. Ltd.; Pfizer Inc.; Seattle Genetics Inc.; Stemline Therapeutics Inc.; Sunesis Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics Inc.; Trovagene Inc.; Akebia Therapeutics Inc.; Allogene Therapeutics Inc.; Blueprint Medicines Corporation; Karyopharm Therapeutics Inc.; Verastem Oncology Inc.
Get The Full Global Leukemia Therapeutics Market Report
Leukemia Therapeutics Market Overview
Leukemia therapeutics refer to a treatment used to treat an aggressive (quickly spreading) malignancy in which the blood or bone marrow contain an excessive amount of myeloblasts (immature white blood cells). The type treatment for leukemia depends on various factors such as age, overall health, type of leukemia, its current condition within the body and others.
Leukemia Therapeutics Global Market Report 2023 provides data on the global leukemia therapeutics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The leukemia therapeutics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.